-
公开(公告)号：US20110097340A1
公开(公告)日：2011-04-28
申请号：US12739383
申请日：2008-10-20
申请人： Sumant Ramachandra , Walter Robert Bishop , Linda Masat , Chao Bai Huang , Toshihiko Takeuchi , Seema Kantak , Chin-Yi Huang's
发明人： Sumant Ramachandra , Walter Robert Bishop , Linda Masat , Chao Bai Huang , Toshihiko Takeuchi , Seema Kantak , Chin-Yi Huang's
IPC分类号： A61K39/395 , C12P21/06 , C12N5/10 , C12N15/63 , C07K14/435 , C07K16/22 , A61P27/02 , A61P35/00 , C07H21/04 , A61P3/10
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/00 , Y10S435/81
摘要： Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
摘要翻译： 本文公开了完全人抗体及其抗原结合片段，其特异性结合人VEGF并抑制VEGF与VEGF-R1和VEGF-R2的结合，因此抑制VEGF信号传导。 本文公开的抗体和抗原结合片段可用于例如在体内和体外治疗血管生成和与血管发生相关的病症。
-
公开(公告)号：US08216571B2
公开(公告)日：2012-07-10
申请号：US12739383
申请日：2008-10-20
申请人： Sumant Ramachandra , Walter Robert Bishop , Linda Masat , Chao Bai Huang , Toshihiko Takeuchi , Seema Kantak , Chin-Yi Huang
发明人： Sumant Ramachandra , Walter Robert Bishop , Linda Masat , Chao Bai Huang , Toshihiko Takeuchi , Seema Kantak , Chin-Yi Huang
IPC分类号： A61K39/395 , A61K39/00 , C07K16/00 , C07K16/18 , C07K16/22 , C07K16/42 , C12P21/08 , C12P21/02
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/00 , Y10S435/81
摘要： Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
摘要翻译： 本文公开了完全人抗体及其抗原结合片段，其特异性结合人VEGF并抑制VEGF与VEGF-R1和VEGF-R2的结合，因此抑制VEGF信号传导。 本文公开的抗体和抗原结合片段可用于例如在体内和体外治疗血管生成和与血管发生相关的病症。
-
公开(公告)号：US20110076279A1
公开(公告)日：2011-03-31
申请号：US12446438
申请日：2007-10-22
IPC分类号： A61K39/395 , C07K16/22 , C07H21/00 , C12N15/63 , C12N5/10 , A61P29/00 , A61P19/02 , A61P17/06 , A61P17/00 , A61P11/00 , A61P11/06 , A61P27/02 , A61P35/00
CPC分类号： C07K16/22 , C07K2317/21 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Vascular endothelial growth factor (VEGF) overexpression is associated with a variety of conditions involving aberrant angiogenesis. Disclosed herein are fully human antibodies that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling Based on their ability to inhibit VEGF signaling, the antibodies disclosed herein may be used to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
摘要翻译： 血管内皮生长因子（VEGF）过表达与涉及异常血管发生的多种病症有关。 本文公开了完全人抗体，其特异性结合人VEGF并抑制VEGF结合VEGF-R1和VEGF-R2，因此抑制VEGF信号传导基于其抑制VEGF信号传导的能力，本文公开的抗体可用于治疗血管发生和病症 与体内和体外的血管发生相关。
-
公开(公告)号：US20150317891A1
公开(公告)日：2015-11-05
申请号：US14700357
申请日：2015-04-30
申请人： William Kenneth Day , Steve Joseph Lindo , Paul John Foryt , Justin Joseph Schmidt , Robert Cousineau , Michael Kremliovsky , Sumant Ramachandra , Anatoly S. Belkin , Gary Mills
发明人： William Kenneth Day , Steve Joseph Lindo , Paul John Foryt , Justin Joseph Schmidt , Robert Cousineau , Michael Kremliovsky , Sumant Ramachandra , Anatoly S. Belkin , Gary Mills
CPC分类号： A61M5/142 , A61M2205/18 , A61M2205/3553 , A61M2205/3584 , A61M2205/3592 , A61M2205/52 , G06F19/00 , G06F19/30 , G06F19/3468 , G08B21/0461 , G16H40/63
摘要： A patient care system is disclosed that includes a medical device such as an infusion pump. The medical device generates a data message containing information such as the status of the therapy being delivered, operating data or both. An alarm generating system assesses the data message from the pump and generates an alarm message if certain conditions established by a first set of rules are met. The alarm message is assessed according to a second set of rules as to whether to suppress the alarm message. The data message contains a required input for both the first and second algorithms. A dispatching system is adapted to forward the alarm message to an alarm destination according to a third set of rules. The alarm destination expresses an alarm upon receipt of the alarm message.
摘要翻译： 公开了包括诸如输液泵的医疗装置的病人护理系统。 医疗设备产生包含诸如正在传递的治疗的状态，操作数据或两者的信息的数据消息。 报警生成系统从泵抽出数据信息，并且如果满足第一组规则建立的某些条件，则会产生报警信息。 根据关于是否抑制报警消息的第二组规则评估报警消息。 数据消息包含第一和第二算法所需的输入。 调度系统适用于根据第三组规则将报警信息转发到报警目的地。 报警目的地在收到报警信息后发出报警。
-
公开(公告)号：US20080319039A1
公开(公告)日：2008-12-25
申请号：US11767847
申请日：2007-06-25
IPC分类号： A61K31/4188 , A61P35/00
CPC分类号： A61K31/495 , A61K9/4883
摘要： This invention relates to unit dosage forms of temozolomide. These unit dosage forms are particularly well-suited for decreasing the pill burden and increasing patient compliance. The invention also relates to methods of treating proliferative disorders in a patient with these unit dosage forms. The invention additionally relates to kits comprising these unit dosage forms.
摘要翻译： 本发明涉及替莫唑胺的单位剂量形式。 这些单位剂型特别适合于减少药丸负担并增加患者依从性。 本发明还涉及用这些单位剂型治疗患者的增殖性疾病的方法。 本发明还涉及包含这些单位剂型的试剂盒。
-
-
-
-
搜索结果
5 条记录 (耗时 0.037 秒)
